In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia in the daily life of participants with type 1 Diabetes

Inclusion Criteria:

• Body mass index between 20 and 27 kg/m2
• T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c <69 mmol/mol (<8.5%)
• Treatment with a stable insulin regimen ≥3 months
• T1D duration between 2 and 15years
• C-peptide negative (C-peptide ≤ 16 ng/ml)
• Informed consent

Exclusion Criteria:

• Anemia (hemoglobin outside normal range)
• Known liver disease and/or ALAT and/or ASAT > 2 times normal values
• Estimated glomerular filtration rate (eGFR) ≤60 ml/min/1.73 m2 or albuminuria
• Prior Cardiovascular events and/or abnormal heart rate/blood pressure
• Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to randomization
• Any physical or psychological condition that the investigator feels would interfere with trial participation

Caucasian men

The peptides/placebo is prepared, in a randomized fashion, by a laboratory assistant.